Photo/Shetuwang
Brukinsa, the mantle cell lymphoma treatment developed by China's BeiGene, was approved by the U.S. Food and Drug Administration Thursday, becoming the first cancer medicine developed in China to be approved in the U.S. Stock of BeiGene (NASDAQ: BGNE) rose by 3.36% in after-hours trading by press time.
Editor:
Li Menglin
川公网安备 51019002001991号
